Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients

Study identifier:D1441C00003

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

The effect of Quetiapine on psychotic-like symptoms in borderline personality disordered patients: A Randomised Placebo-Controlled Trial

Medical condition

Borderline personality disorder

Phase

Phase 2

Healthy volunteers

No

Study drug

Quetiapine fumarate, Placebo

Sex

All

Actual Enrollment

40

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 01 Jun 2004
Primary Completion Date: -
Study Completion Date: 01 Jun 2007

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria